These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 8648861)

  • 1. Estrogen replacement therapy and endometrial hyperplasia.
    Tsang P
    JAMA; 1996 Jun; 275(24):1880-1. PubMed ID: 8648861
    [No Abstract]   [Full Text] [Related]  

  • 2. Reversal by medical treatment of endometrial hyperplasia caused by estrogen replacement therapy.
    Figueroa-Casas PR; Ettinger B; Delgado E; Javkin A; Vieder C
    Menopause; 2001; 8(6):420-3. PubMed ID: 11723414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial.
    JAMA; 1996 Feb; 275(5):370-5. PubMed ID: 8569016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathologic features associated with resolution of complex atypical hyperplasia and grade 1 endometrial adenocarcinoma after progestin therapy.
    Gunderson CC; Dutta S; Fader AN; Maniar KP; Nasseri-Nik N; Bristow RE; Diaz-Montes TP; Palermo R; Kurman RJ
    Gynecol Oncol; 2014 Jan; 132(1):33-7. PubMed ID: 24316307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The "red queen" and endometrial hyperplasia.
    Gambrell RD
    Fertil Steril; 1994 Feb; 61(2):401-2. PubMed ID: 8299806
    [No Abstract]   [Full Text] [Related]  

  • 6. Down-regulation of bcl-2 is a potential marker of the efficacy of progestin therapy in the treatment of endometrial hyperplasia.
    Amezcua CA; Zheng W; Muderspach LI; Felix JC
    Gynecol Oncol; 1999 Apr; 73(1):126-36. PubMed ID: 10094893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estradiol-induced hyperplasia in endometrial biopsies from women on hormone replacement therapy.
    Wright TC; Holinka CF; Ferenczy A; Gatsonis CA; Mutter GL; Nicosia S; Richart RM
    Am J Surg Pathol; 2002 Oct; 26(10):1269-75. PubMed ID: 12360041
    [No Abstract]   [Full Text] [Related]  

  • 8. Complex endometrial hyperplasia in the context of tibolone administration.
    Kane SC; Quinn MA
    Aust N Z J Obstet Gynaecol; 2009 Jun; 49(3):338-9. PubMed ID: 19566575
    [No Abstract]   [Full Text] [Related]  

  • 9. Biochemical and immunohistochemical estrogen and progesterone receptors in adenomatous hyperplasia and endometrial carcinoma: correlations with stage and other clinicopathologic features.
    Nyholm HC; Nielsen AL; Lyndrup J; Norup P; Thorpe SM
    Am J Obstet Gynecol; 1992 Nov; 167(5):1334-42. PubMed ID: 1442987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progestin therapy for perimenopausal women.
    Kase NG
    J Reprod Med; 1982 Aug; 27(8 Suppl):522-30. PubMed ID: 7131445
    [No Abstract]   [Full Text] [Related]  

  • 11. Endometrial hyperplasia following estrogen treatment without the addition of gestagen. A follow-up study after withdrawal of estrogens.
    Lindahl B; Willén R
    Anticancer Res; 1991; 11(6):2071-3. PubMed ID: 1776842
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of hormone replacement therapy on the endometrium and lipid parameters: a review of randomized clinical trials, 1985 to 1995.
    Pickar JH; Thorneycroft I; Whitehead M
    Am J Obstet Gynecol; 1998 May; 178(5):1087-99. PubMed ID: 9609589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estrogen replacement therapy and endometrial hyperplasia.
    Subbiah MT
    JAMA; 1996 Jun; 275(24):1880-1. PubMed ID: 8648860
    [No Abstract]   [Full Text] [Related]  

  • 14. Withdrawal bleeding and endometrial safety.
    Padwick M
    Lancet; 1994 Dec; 344(8938):1703-4. PubMed ID: 7996980
    [No Abstract]   [Full Text] [Related]  

  • 15. Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding.
    Lethaby A; Farquhar C; Sarkis A; Roberts H; Jepson R; Barlow D
    Cochrane Database Syst Rev; 2000; (2):CD000402. PubMed ID: 10796715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Introduction to steroids in the menopause.
    Samsioe G
    Am J Obstet Gynecol; 1992 Jun; 166(6 Pt 2):1980-5. PubMed ID: 1605288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Failure of down-regulation of estrogen receptors and progesterone receptors after medroxyprogesterone acetate administration for endometrial hyperplasias.
    Masuzawa H; Badokhon NH; Nakayama K; Konishi I; Nikaido T; Fujii S
    Cancer; 1994 Oct; 74(8):2321-8. PubMed ID: 7922983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased natural killer cells and decreased regulatory T cells are seen in complex atypical endometrial hyperplasia and well-differentiated carcinoma treated with progestins.
    Witkiewicz AK; McConnell T; Potoczek M; Emmons RV; Kurman RJ
    Hum Pathol; 2010 Jan; 41(1):26-32. PubMed ID: 19733383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hormone therapy in postmenopausal women and risk of endometrial hyperplasia: a Cochrane review summary.
    Roberts H; Hickey M; Lethaby A
    Maturitas; 2014 Jan; 77(1):4-6. PubMed ID: 24182544
    [No Abstract]   [Full Text] [Related]  

  • 20. Estrogen and progesterone receptor expression in postmenopausal tamoxifen-exposed endometrial pathologies.
    Cohen I; Beyth Y; Altaras MM; Shapira J; Tepper R; Cardoba M; Yigael D; Figer A; Fishman A; Berenhein J
    Gynecol Oncol; 1997 Oct; 67(1):8-15. PubMed ID: 9345349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.